Hemodynamic Impact of Cytosorb and CKRT in Children With Septic Shock
Launched by OSPEDALE PEDIATRICO BAMBIN GESÙ · Dec 13, 2022
Trial Information
Current as of February 05, 2025
Completed
Keywords
ClinConnect Summary
Prospective interventional pilot study included children with septic shock, weight ≥ 10 Kgs and requiring continuous kidney replacement therapy. Cytosorb (CytoSorbents Inc, New Jersey, USA) cartridge was added to CKRT every 24 hours for a maximum of 96 hours. A control group of matched patients was also identified from an external database. The primary outcome of the study was the proportion of patients who achieved an equal or more than 50% relative reduction in vasopressors or inotropes dose from baseline to the end of treatment. Secondary outcomes included doses of vasopressors and inotr...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Children weighing ≥ 10 kg
- • 2. Septic shock as defined by the International Pediatric Consensus Conference
- • 3. Need for Continuous Renal Replacement Therapy (CRRT) = acute kidney injury defined by the KDIGO criteria (16) AND/OR fluid overload ≥ 10%
- Exclusion Criteria:
- • Refused consensus by parents
- • Concomitant use of other extracorporeal blood purification techniques.
About Ospedale Pediatrico Bambin Gesù
Ospedale Pediatrico Bambin Gesù is a renowned pediatric hospital in Italy, dedicated to providing exceptional healthcare for children and adolescents. As a leading center for pediatric research and innovation, it actively participates in clinical trials aimed at advancing medical knowledge and improving treatment options for various pediatric conditions. The hospital's multidisciplinary team of specialists collaborates closely with national and international research networks, ensuring adherence to the highest ethical and scientific standards. With a commitment to enhancing patient outcomes, Ospedale Pediatrico Bambin Gesù plays a pivotal role in shaping the future of pediatric medicine through its robust clinical trial initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rome, , Italy
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials